244 related articles for article (PubMed ID: 33254494)
1. Common determinants of severe Covid-19 infection are explicable by SARS-CoV-2 secreted glycoprotein interaction with the CD33-related Siglecs, Siglec-3 and Siglec-5/14.
Murch SH
Med Hypotheses; 2020 Nov; 144():110168. PubMed ID: 33254494
[TBL] [Abstract][Full Text] [Related]
2. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways.
Angata T; Varki A
J Biol Chem; 2000 Jul; 275(29):22127-35. PubMed ID: 10801860
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells.
Lock K; Zhang J; Lu J; Lee SH; Crocker PR
Immunobiology; 2004; 209(1-2):199-207. PubMed ID: 15481154
[TBL] [Abstract][Full Text] [Related]
4. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.
Ikehara Y; Ikehara SK; Paulson JC
J Biol Chem; 2004 Oct; 279(41):43117-25. PubMed ID: 15292262
[TBL] [Abstract][Full Text] [Related]
5. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?
Cao H; Crocker PR
Immunology; 2011 Jan; 132(1):18-26. PubMed ID: 21070233
[TBL] [Abstract][Full Text] [Related]
6. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
Avril T; Floyd H; Lopez F; Vivier E; Crocker PR
J Immunol; 2004 Dec; 173(11):6841-9. PubMed ID: 15557178
[TBL] [Abstract][Full Text] [Related]
7. Ganglioside binding pattern of CD33-related siglecs.
Rapoport E; Mikhalyov I; Zhang J; Crocker P; Bovin N
Bioorg Med Chem Lett; 2003 Feb; 13(4):675-8. PubMed ID: 12639556
[TBL] [Abstract][Full Text] [Related]
8. OB-BP1/Siglec-6. a leptin- and sialic acid-binding protein of the immunoglobulin superfamily.
Patel N; Brinkman-Van der Linden EC; Altmann SW; Gish K; Balasubramanian S; Timans JC; Peterson D; Bell MP; Bazan JF; Varki A; Kastelein RA
J Biol Chem; 1999 Aug; 274(32):22729-38. PubMed ID: 10428856
[TBL] [Abstract][Full Text] [Related]
9. Cloning and characterization of human Siglec-11. A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia.
Angata T; Kerr SC; Greaves DR; Varki NM; Crocker PR; Varki A
J Biol Chem; 2002 Jul; 277(27):24466-74. PubMed ID: 11986327
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy approaches on innate immunity for SARS-Cov-2.
Arslan BA; Timucin AC
Acta Virol; 2020; 64(4):389-395. PubMed ID: 32985199
[TBL] [Abstract][Full Text] [Related]
11. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
12. Natural ligands for CD33-related Siglecs?
Varki A
Glycobiology; 2009 Aug; 19(8):810-2. PubMed ID: 19429924
[No Abstract] [Full Text] [Related]
13. A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33.
Whitney G; Wang S; Chang H; Cheng KY; Lu P; Zhou XD; Yang WP; McKinnon M; Longphre M
Eur J Biochem; 2001 Dec; 268(23):6083-96. PubMed ID: 11733002
[TBL] [Abstract][Full Text] [Related]
14. High-affinity ligands of Siglec receptors and their therapeutic potentials.
Magesh S; Ando H; Tsubata T; Ishida H; Kiso M
Curr Med Chem; 2011; 18(23):3537-50. PubMed ID: 21756229
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition.
Freeman S; Birrell HC; D'Alessio K; Erickson-Miller C; Kikly K; Camilleri P
Eur J Biochem; 2001 Mar; 268(5):1228-37. PubMed ID: 11231274
[TBL] [Abstract][Full Text] [Related]
16. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.
Läubli H; Alisson-Silva F; Stanczak MA; Siddiqui SS; Deng L; Verhagen A; Varki N; Varki A
J Biol Chem; 2014 Nov; 289(48):33481-91. PubMed ID: 25320078
[TBL] [Abstract][Full Text] [Related]
17. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice.
Brinkman-Van der Linden EC; Angata T; Reynolds SA; Powell LD; Hedrick SM; Varki A
Mol Cell Biol; 2003 Jun; 23(12):4199-206. PubMed ID: 12773563
[TBL] [Abstract][Full Text] [Related]
18. Basic and clinical immunology of Siglecs.
von Gunten S; Bochner BS
Ann N Y Acad Sci; 2008 Nov; 1143():61-82. PubMed ID: 19076345
[TBL] [Abstract][Full Text] [Related]
19. Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer's disease.
Gonzalez-Gil A; Porell RN; Fernandes SM; Maenpaa E; Li TA; Li T; Wong PC; Aoki K; Tiemeyer M; Yu ZJ; Orsburn BC; Bumpus NN; Matthews RT; Schnaar RL
J Biol Chem; 2022 Jun; 298(6):101960. PubMed ID: 35452678
[TBL] [Abstract][Full Text] [Related]
20. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
